Risedronic acid

Risedronic acid
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
    Routes of
    administration    		 Oral
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Bioavailability 0.63%
    Protein binding ~24%
    Metabolism None
    Elimination half-life 1.5 h
    Excretion Renal and fecal
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    ChEMBL
    ECHA InfoCard 100.116.436 Edit this at Wikidata
    Chemical and physical data
    Formula C7H11NO7P2
    Molar mass 283.112 g/mol
    3D model (JSmol)
     ☒N☑Y (what is this?)  (verify)

    Risedronic acid (INN) often used as its sodium salt risedronate sodium (USAN) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.

    Controversies

    In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.[1] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".[2]

    In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports[3] and discussion).[4]

    In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.

    See also

    References

    1. ↑ "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.
    2. ↑ NY fed judge finds promotions for bone drug Boniva are fair Associated Press, 7 Sept 2006
    3. ↑ http://www.thejabberwock.org/wiki/index.php?title=Actonel_Case_Media_Reports
    4. ↑ "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.